These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23027418)

  • 1. Muscarinic mechanisms in psychotic disorders.
    McKinzie DL; Bymaster FP
    Handb Exp Pharmacol; 2012; (213):233-65. PubMed ID: 23027418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
    Mirza NR; Peters D; Sparks RG
    CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
    Andersen MB; Fink-Jensen A; Peacock L; Gerlach J; Bymaster F; Lundbaek JA; Werge T
    Neuropsychopharmacology; 2003 Jun; 28(6):1168-75. PubMed ID: 12700711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel M(1) allosteric ligands: a patent review.
    Kuduk SD; Beshore DC
    Expert Opin Ther Pat; 2012 Dec; 22(12):1385-98. PubMed ID: 23092292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions.
    Bolbecker AR; Shekhar A
    Handb Exp Pharmacol; 2012; (208):167-90. PubMed ID: 22222699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.
    Shannon HE; Rasmussen K; Bymaster FP; Hart JC; Peters SC; Swedberg MD; Jeppesen L; Sheardown MJ; Sauerberg P; Fink-Jensen A
    Schizophr Res; 2000 May; 42(3):249-59. PubMed ID: 10785583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia.
    Paul SM; Yohn SE; Popiolek M; Miller AC; Felder CC
    Am J Psychiatry; 2022 Sep; 179(9):611-627. PubMed ID: 35758639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antipsychotic potential of muscarinic allosteric modulation.
    Bridges TM; LeBois EP; Hopkins CR; Wood MR; Jones CK; Conn PJ; Lindsley CW
    Drug News Perspect; 2010 May; 23(4):229-40. PubMed ID: 20520852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?
    Scarr E; Dean B
    J Neurochem; 2008 Dec; 107(5):1188-95. PubMed ID: 18957051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.
    Watt ML; Schober DA; Hitchcock S; Liu B; Chesterfield AK; McKinzie D; Felder CC
    J Pharmacol Exp Ther; 2011 Aug; 338(2):622-32. PubMed ID: 21558436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia.
    Dean B
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1563-71. PubMed ID: 22283751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
    Barak S; Weiner I
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscarinic receptors as a target for drugs treating schizophrenia.
    Bymaster FP; Felder C; Ahmed S; McKinzie D
    Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):163-81. PubMed ID: 12769625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schizophrenia: moving beyond monoamine antagonists.
    Conn PJ; Tamminga C; Schoepp DD; Lindsley C
    Mol Interv; 2008 Apr; 8(2):99-107. PubMed ID: 18403654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials.
    McArthur RA; Gray J; Schreiber R
    Curr Opin Investig Drugs; 2010 Jul; 11(7):740-60. PubMed ID: 20571970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents.
    Bymaster FP; Felder CC
    Mol Psychiatry; 2002; 7 Suppl 1():S57-63. PubMed ID: 11986996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
    Shekhar A; Potter WZ; Lightfoot J; Lienemann J; Dubé S; Mallinckrodt C; Bymaster FP; McKinzie DL; Felder CC
    Am J Psychiatry; 2008 Aug; 165(8):1033-9. PubMed ID: 18593778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel derivatives of the muscarinic agonist tetra(ethylene glycol)(3-methoxy-1,2,5-thiadiazol-4-yl) [3-(1-methyl-1,2,5,6-tetrahydropyrid-3-yl)-1,2,5-thiadiazol-4-yl] ether (CDD-0304): effects of structural modifications on the binding and activity at muscarinic receptor subtypes and chimeras.
    Tejada FR; Nagy PI; Xu M; Wu C; Katz T; Dorsey J; Rieman M; Lawlor E; Warrier M; Messer WS
    J Med Chem; 2006 Dec; 49(25):7518-31. PubMed ID: 17149881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscarinic mechanisms of antipsychotic atypicality.
    Bymaster FP; Felder CC; Tzavara E; Nomikos GG; Calligaro DO; Mckinzie DL
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1125-43. PubMed ID: 14642972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.